Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 29Carcinoma, Non-Small-Cell Lung 11Liver Neoplasms 7Lung Neoplasms 5Urinary Bladder Neoplasms 4Small Cell Lung Carcinoma 4Neoplasms 4Diabetes Mellitus, Insulin-Dependent, 12 4Pancreatic Neoplasms 3Colorectal Neoplasms 3Cholangiocarcinoma 3Biliary Tract Neoplasms 3Adenocarcinoma Of Esophagus 3Stomach Neoplasms 2Neoplasm Metastasis 2Mesothelioma, Malignant 2Mesothelioma 2Fallopian Tube Neoplasms 2Carcinoma 2Vascular Neoplasms 1Urothelial Cancer 1Urethral Neoplasms 1Ureteral Neoplasms 1Unresectable Hepatocellular Carcinoma 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Solid Malignancies 1Seminoma 1

Interventions

Liver Transplantation 2tremelimumab 1durvalumab 1Diagnostic Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypertension, Portal × tremelimumab × 1 year × Clear all
NCT05027425 2026-05-06

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

University of Cincinnati

Phase 2 Terminated
8 enrolled 9 charts
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡